GoAI
Get started
Zura Bio Limited logo

Zura Bio Limited

ZURA

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.85

+$0.10 · +1.74%

Aug 21, 4:00 PM ET

ZURA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

60

Neutral

Sentiment

41

Mixed

Risk resilience

47

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Sandeep C. Kulkarni
Listed since
Mar 21, 2023
Employees
40

Market position

Day range

Current $5.85

52-week range

Current $5.85

Open
$5.755
Previous close
$5.75
Volume
724.89K
0.75× average
Average volume
966.29K
Average daily volume
Market cap
555.74M USD
Beta
-0.04
Market reference 1
50-day average
$5.1746
+13.05% above average
200-day average
$5.1429
+13.75% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
383.99M USD
EV / EBITDA
-5.6×
Earnings yield
-13.91%
Free cash flow yield
-13.16%

Profitability & efficiency

Return on equity
-67.61%
Return on assets
-60.25%
Return on invested capital
-74.11%

Financial health

Current ratio
9.05×
Altman Z-score
18.33
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−75.25M USD-36.34%

Net income

−68.65M USD-31.00%
Income trends across reported periods16.78M USD−16.68M USD−50.15M USD−83.61M USDOperating income, FY2021: −1.09M USDOperating income, FY2022: −27.16M USDOperating income, FY2023: −62.64M USDOperating income, FY2024: −55.19M USDOperating income, FY2025: −75.25M USDNet income, FY2021: 8.42M USDNet income, FY2022: −25.74M USDNet income, FY2023: −60.36M USDNet income, FY2024: −52.4M USDNet income, FY2025: −68.65M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −1.09M USD. Operating income FY2022 −27.16M USD. Operating income FY2023 −62.64M USD. Operating income FY2024 −55.19M USD. Operating income FY2025 −75.25M USD. Net income FY2021 8.42M USD. Net income FY2022 −25.74M USD. Net income FY2023 −60.36M USD. Net income FY2024 −52.4M USD. Net income FY2025 −68.65M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development42.08M USD24.4M USD44M USD23.69M USD—
Selling, general, and administrative33.16M USD30.79M USD18.64M USD3.47M USD1.09M USD
Operating expenses75.25M USD55.19M USD62.64M USD27.16M USD1.09M USD
Interest income6.34M USD8M USD2.19M USD570 USD23.48K USD
Depreciation and amortization49K USD9K USD———
Operating income−75.25M USD−55.19M USD−62.64M USD−27.16M USD−1.09M USD
Net income−68.65M USD−52.4M USD−60.36M USD−25.74M USD8.42M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 7 misses, 0 met estimates
Average EPS surprise
-19.86%
11 comparable reports
Latest EPS result
-0.21
Estimate -0.19 · Miss by 9.78%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.12-0.26-0.39-0.53Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 25, 2025: actual -0.14, estimate -0.16, surprise +12.50%, Beat. Q2 2025, reported May 8, 2025: actual -0.19, estimate -0.17, surprise -11.76%, Miss. Q3 2025, reported Aug 14, 2025: actual -0.17, estimate -0.19, surprise +10.53%, Beat. Q4 2025, reported Nov 13, 2025: actual -0.21, estimate -0.19, surprise -10.53%, Miss. Q1 2026, reported Mar 19, 2026: actual -0.49, estimate -0.18, surprise -172.22%, Miss. Q2 2026, reported May 7, 2026: actual -0.22, estimate -0.17, surprise -29.41%, Miss. Q3 2026, reported Aug 11, 2026: actual -0.21, estimate -0.191, surprise -9.78%, Miss. Q4 2026, reported Nov 12, 2026: actual —, estimate -0.22, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$20.00

241.88% upside
Past 12 months12-month forecast

Price history unavailable

High $20.00Average $20.00Low $20.00

Rating distribution

8 ratings
Strong buy113%
Buy675%
Hold113%
Sell00%
Strong sell00%

Recent analyst actions

7 institutions
Cantor FitzgeraldmaintainOverweight
Piper SandlermaintainOverweight

ZURA news

businesswire.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of…

Read source
gurufocus.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the

Read source
businesswire.com

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious…

Read source
defenseworld.net

Zura Bio Limited (NASDAQ:ZURA) Receives $10.75 Average Target Price from Brokerages

Shares of Zura Bio Limited (NASDAQ: ZURA - Get Free Report) have received an average rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One equities research analyst…

Read source
defenseworld.net

Zura Bio (NASDAQ:ZURA) Trading 5.3% Higher – Here’s Why

Zura Bio Limited (NASDAQ: ZURA - Get Free Report)'s share price rose 5.3% during trading on Friday. The company traded as high as $5.52 and last traded at $5.5280. 150,021 shares were traded during trading, a decline of…

Read source
benzinga.com

Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio's Lead Therapy

On Wednesday, William Blair initiated coverage of Zura Bio Limited (NASDAQ:ZURA) with an Outperform rating, citing the potential of its lead candidate, tibulizumab, to deliver differentiated efficacy across severe…

Read source

ZURA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ZURA

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.06M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.79M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
ALPS Medical Breakthroughs ETF logoALPS Medical Breakthroughs ETFSBIO
Market value
650.93K
Weight
0.28%
AUM
236.37M USD
Expense ratio
0.50%
Price / 1D
$69.11+0.80%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
345.9K
Weight
0.02%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%
Global X - Russell 2000 ETF logoGlobal X - Russell 2000 ETFRSSL
Market value
163.14K
Weight
0.01%
AUM
1.53B USD
Expense ratio
0.08%
Price / 1D
$117.49+0.86%
Vanguard Russell 3000 ETF logoVanguard Russell 3000 ETFVTHR
Market value
27.29K
Weight
0.00%
AUM
6.1B USD
Expense ratio
0.06%
Price / 1D
$338.91+0.49%

Continue in GoAI

Research ZURA

research.disclaimer